DDInter107 DDInter1658
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eplerenone
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polatuzumab vedotin
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Isavuconazonium
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Abemaciclib
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Eplerenone
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib